919103-31-4Relevant articles and documents
BETA-LACTAMASE INHIBITORS
-
, (2013/04/25)
Disclosed herein inter alia are Boron containing compounds and methods for treating infections related to antibiotic resistant microorganisms.
Crystal structure of a complex between the actinomadura R39 dd -peptidase and a peptidoglycan-mimetic boronate inhibitor: Interpretation of a transition state analogue in terms of catalytic mechanism
Dzhekieva, Liudmila,Rocaboy, Mathieu,Kerff, Frederic,Charlier, Paulette,Sauvage, Eric,Pratt
, p. 6411 - 6419 (2011/04/16)
The Actinomadura R39 dd-peptidase is a bacterial low molecular weight class C penicillin-binding protein. It has previously been shown to catalyze hydrolysis and aminolysis of small d-alanyl-d-alanine terminating peptides, especially those with a side cha
Boro-norleucine as a P1 residue for the design of selective and potent DPP7 inhibitors
Shreder, Kevin R.,Wong, Melissa S.,Corral, Sergio,Yu, Zhizhou,Winn, David T.,Wu, Min,Hu, Yi,Nomanbhoy, Tyzoon,Alemayehu, Senaiet,Fuller, Stacy R.,Rosenblum, Jonathan S.,Kozarich, John W.
, p. 4256 - 4260 (2007/10/03)
Dipeptide-based inhibitors with C-substituted (alkyl or aminoalkyl) α-amino acids in the P2 position and boro-norleucine (boro-Nle) in the P1 position were synthesized. Relative to boro-proline, boro-Nle as a P1 residue was shown able to significantly dial out DPP4, FAP, DPP8, and DPP9 activity. Dab-boro-Nle (4g) proved to be the most selective and potent DPP7 inhibitor with a DPP7 IC50 value of 480 pM.